Preparation, characterisation and antibacterial property of ciprofloxacin-loaded nanostructured lipid carrier for treatment of infection.

In this study, controlled ciprofloxacin (CIPRO) nanostrustructured lipid carriers of Precirol ATO 5/Transcutol HP (batch A) and tallow fat/Transcutol HP (batch B) was carreid out. Objective: The aim was to improve solubility and bioavailability of CIPRO. Study of controlled ciprofloxacin (CIPRO) nanostructured lipid carriers of Precirol ATO 5/Transcutol HP (batch A) and tallow fat/Transcutol HP (batch B). CIPRO concentrations C (0.0, 0.2, 0.5, 0.8, and 1.0% w/w) as AC and BC were prepared by hot homogenisation and characterised by zetasizer, differential scanning calorimetry, Fourier transform infra-red spectroscopy, drug release and growth inhibitory zone diameter (IZD) on agar-seeded . AC achieved polydispersed particles of ∼605 nm, 92% encapsulation efficiency (EE) and -28 mV similar to BC (∼789 nm, 91% EE, and -31 mV). Crystallinity indices (AC and BC) were low at 3 and 5%, respectively. CIPRO release in AC was ∼98% in SGF (pH 1.2) and BC similarly ∼98% in SIF (pH 6.8). AC had superior growth inhibition of at lower concentration (1.2 µg/mL) than BC and CIPRO controls; hence could serve as possible sustained delivery system of CIPRO.